Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Glioblastoma patients with modified PTEN have resistance to EGFR inhibitors

Glioblastoma patients with modified PTEN have resistance to EGFR inhibitors

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Allergies may reduce risk of brain cancer

Allergies may reduce risk of brain cancer

New insight into why glioblastoma multiforme recurs in adults

New insight into why glioblastoma multiforme recurs in adults

Fusion of FGFR and TACC gene leads to glioblastoma

Fusion of FGFR and TACC gene leads to glioblastoma

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

LSDF announces $570,000 in awards to support commercialization of new health-related products

LSDF announces $570,000 in awards to support commercialization of new health-related products

Neural precursor cells suppress aggressive tumors

Neural precursor cells suppress aggressive tumors

Ampio announces advancement of NCE001 to preclinical development

Ampio announces advancement of NCE001 to preclinical development

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

GBM patients with CNP subtype may have less aggressive subtype of cancer

GBM patients with CNP subtype may have less aggressive subtype of cancer

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Study reveals why GBM is highly resistant to current chemotherapies

Study reveals why GBM is highly resistant to current chemotherapies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.